Study guide

13.2 Illinois Compounding Rules & Beyond-Use Dates

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

13.2 Illinois Compounding Rules & Beyond-Use Dates

Key Takeaways Explain This Topic AI

Beyond-use dates (BUDs) are assigned using USP <795>/<797> frameworks (and stability data when available)—they are not the same as manufacturer expiration dates on unopened commercial products.

Commonly tested revised <795> default BUD anchors (without CNSP-specific stability data): non-preserved aqueous forms often max 14 days refrigerated; preserved aqueous up to 35 days; nonaqueous oral liquids up to 90 days—always verify against current official USP and do not invent extra tables.

Illinois 1330.640 requires patient-specific compounding as the default, detailed office-use rules for limited nonsterile stock, exclusive compounding space, logbooks, 5-year records, special compound labeling language, and temperature-controlled off-site delivery.

503A traditional compounding pharmacies prepare for identified patients under state/USP rules; 503B outsourcing facilities register with FDA, follow cGMP, and may compound without patient-specific prescriptions under federal 503B conditions.

Inspection readiness means producing MFRs/CRs, training files, USP references, equipment/calibration evidence, HD controls if applicable, and proof the sterile area was Department-approved if sterile services were added.

Last updated: August 2026

13.2 Illinois Compounding Rules & Beyond-Use Dates

Quick Answer: Assign beyond-use dates (BUDs) with the official USP <795> (nonsterile) and USP <797> (sterile) frameworks—using stability data when available and default maximums when not. Illinois 68 Ill. Adm. Code 1330.640 requires patient-specific compounding as the default, limits office use , mandates equipment/space/records , dictates compound labels (including a required “specifically compounded for you” statement), and holds the PIC to training and sterile add-on inspection duties. Distinguish 503A traditional compounding pharmacies from 503B outsourcing facilities. Be inspection-ready : master formulation records, compounding records, lots/expirations, BUDs, and sterile-area approval.

Section 13.1 taught which standards apply . This section teaches how long compounds may be used , what Illinois operational rules require day to day , and how federal 503A/503B models differ —all high-yield for NABP 4.5 Compounding and related operations items.

  • Beyond-Use Dates: Framework First, Not Guesswork
  • BUD vs manufacturer expiration date
  • Concept Applies to Meaning
  • Manufacturer expiration date Unopened commercial product stored as labeled Manufacturer-supported shelf life

Beyond-use date (BUD) Compounded preparation (and sometimes opened/manipulated products under other standards) Date/time after which the compounded preparation should not be stored or used, assigned by the compounder under USP rules

Never automatically copy a bulk ingredient’s expiration date onto a multi-ingredient aqueous cream and call it a year-long BUD. Water activity, sterility risk, packaging, storage temperature, and process controls drive BUDs.

Nonsterile BUDs under revised USP <795> (teach carefully)

USP revised <795> (official November 1, 2023 ) uses a water-activity / aqueous vs nonaqueous approach and sets maximum default BUDs when the compounder lacks CNSP-specific stability information. Exact official tables can be updated— exam strategy : know the logic and the commonly tested default anchors from current training materials; if a stem quotes a table, apply the stem; do not invent exotic day counts.

Commonly tested revised <795> default anchors (no CNSP-specific stability data):

  • Preparation type (exam language) Typical default maximum BUD taught on many MPJE/tech banks
  • Non-preserved aqueous dosage form (higher water activity) 14 days under refrigeration
  • Preserved aqueous dosage form Up to 35 days (per revised default framework)
  • Nonaqueous oral liquid (low water activity) Up to 90 days

Solid dosage forms (e.g., capsules) and certain nonaqueous topicals Longer defaults exist in the chapter (often cited up to 180 days for some nonaqueous solids)—still capped by earliest API/excipient expiration and chapter rules

Rules of thumb that survive vignettes:

Aqueous + no preservative → short refrigerated BUD (commonly tested 14 days ).

More water / more microbial risk → shorter BUD.

Stability data specific to the CNSP may support a different BUD within chapter limits —defaults are not a license to ignore data or to exceed chapter maxima.

BUD cannot exceed the shortest remaining expiration of a component when chapter/logic requires that control.

Label the BUD clearly; if time-of-day matters clinically (more common with sterile), include time .

Sterile BUDs under USP <797> (category logic)

Revised <797> (also official November 1, 2023 ) organizes CSPs largely by Category :

Category identity (exam-level) Facility / process idea BUD character

Category 1 Often prepared in a segregated compounding area (SCA) or under limited conditions Shorter BUDs—commonly taught anchors include ≤12 hours controlled room temperature or ≤24 hours refrigerated

Category 2 Prepared in a full cleanroom suite meeting chapter requirements Longer BUDs possible than Category 1, still constrained by sterility/stability factors

Category 3 Additional requirements (e.g., sterility testing and stricter facility/personnel programs as the chapter specifies) Potential for extended BUDs versus Category 2 when all conditions met

Immediate-use Emergent, short start-to-administration windows; not a routine batching pathway Very short use window— not a loophole for anticipatory stock

Teaching discipline for this guide: memorize Category 1 = shorter , Category 2/3 = longer with stricter controls , and the 12-hour / 24-hour Category 1 room-temp/refrigerated anchors commonly tested. Do not invent a full multi-row sterile BUD table from memory on exam day if you are unsure—use the category framework and any numbers the stem supplies.

Storage and shipment interact with BUD

Illinois 1330.640(e)(9) makes the PIC ensure environmental control of preparations shipped or delivered off-site : compounded pharmaceuticals must travel in temperature-controlled delivery containers as defined by USP standards . A correct BUD on the label is worthless if the product baked in a car trunk.

  • Illinois Part 1330 Compounding Operations (1330.640 Deep Dive)
  • Patient-specific default and office-use structure

1330.640(a): A pharmacy may only dispense compounded drugs pursuant to a valid patient-specific prescription , except as provided in the Section.

Nonsterile office use ( 1330.640(d) ) — permitted only when all of the following ideas are satisfied:

  • Quantity does not exceed what the practitioner anticipates using before the BUD
  • Quantity is reasonable for intended use and nature of the practice

Quantity for any one practitioner and for all practitioners overall is not greater than what the pharmacy can compound in compliance with USP identity/strength/quality/purity standards

Records retained ≥ 5 years , readily retrievable, including practitioner identity/contact, date of order, name/strength/qty/dosage form, containers, date compounded, date provided, lot number, and BUD

Label includes pharmacy name/address/phone; name/strength/dosage form and active ingredients; pharmacy lot and BUD; quantity; ancillary storage/caution/HD warnings; and “For Office Use Only – Not for Resale”

Sterile office use: prohibited unless full 503B + wholesale distributor compliance ( 1330.640(c) ). Patient-specific sterile compounds may still go to the prescriber’s office for administration under a valid patient-specific Rx.

Veterinary exception ( 1330.640(g) ): notwithstanding other provisions of the Section, a pharmacy may compound a reasonable quantity of sterile and nonsterile products for office use by a veterinarian .

Sales limits ( 1330.640(e)(10) ): sales of compounded drugs to other pharmacies not under common ownership , or to clinics, hospitals, or manufacturers, are not allowed except office-use pathways and centralized prescription filling contracts under Section 25.5 of the Act (including anticipatory compounding based on routine, readily observed patterns).

Minimum standards and equipment

Every compounding pharmacy must maintain at least:

  • Separate storage area for compounding materials
  • Scales/measuring devices with sufficient accuracy
  • An area used exclusively for compounding

Logbook/record system (lots, component expirations, BUDs) for each nonsterile compound and each sterile compound with BUD > 24 hours

  • Current USP Compounding Compendium (electronic/internet access OK)
  • Veterinary reference if engaged in veterinary compounding (e.g., Plumb’s or Division-approved alternative)
  • Appropriate consumables (capsules, ointment jars, distilled water, etc.)
  • Labeling of compounds dispensed to patients

1330.640(e)(8)(B)–(C) patient-label requirements (permanent label) include, as applicable:

  • Pharmacy name, address, telephone (if not used within the facility)
  • Date dispensed and identifying number (if used off-site)
  • Patient’s name and room number if applicable
  • Name of each drug component , strength, amount, dosage form
  • Directions for use and/or infusion rate if used off-site
  • Prescriber’s name if used off-site
  • Required controlled-substance transfer warnings when applicable
  • Beyond-use date, and time if appropriate
  • Identity of compounding/dispensing pharmacist or authorized individual if used off-site
  • Auxiliary storage labels if applicable

Required statement: “This prescription was specifically compounded in our pharmacy for you at the direction of your prescriber.”

Miss the special compound statement on a vignette and you will lose easy points.

Sterile-specific Illinois add-ons

For sterile compounding, 1330.640(f) adds:

On-hand law texts (Act/Part 1330, Illinois CSA, 77 Ill. Adm. Code 3100, 21 CFR Food & Drugs, Hypodermic Syringes and Needles Act)—electronic OK

A compatibility reference (e.g., ASHP Handbook on Injectable Drugs, King’s Guide, or Division-approved alternative)

File/reference on extended (>24 hours) stability data for finished preparations

Pharmacist accessible at all times ; 24-hour telephone number on labels of compounded drugs and medication infusion devices if used off-site

Emergency medications appropriate for allergic/common adverse effects when dispensing sterile compounds for off-site facilities or home administration (dispensed upon authorized order)

Ingredients from approved/quality sources

Exam-safe ingredient rules (USP + Illinois integrity themes):

  • Prefer USP/NF-grade or other quality-suitable components from FDA-registered establishments when available
  • Do not compound from ingredients of unknown identity, strength, quality, or purity

Do not routinely compound essentially copies of commercially available products without a documented clinical need (federal compounding policy themes)

  • Track lot numbers and expiration dates of components into the compounding record ( 1330.640(e)(4) )
  • Assign BUDs that respect component dating and USP frameworks

“Amazon mystery powder” is never an acceptable active pharmaceutical ingredient source on an MPJE answer.

503A vs 503B (High-Level Distinction)

  • Feature 503A traditional compounding pharmacy 503B outsourcing facility
  • Core statute FD&C Act §503A FD&C Act §503B
  • Patient-specific Rx Required (pharmacy practice model) Not required for each unit under 503B model

Primary overseers State board / IDFPR + FDA boundary enforcement FDA registration/inspection emphasis + state licensure as applicable

Quality system identity USP compounding chapters + state pharmacy rules cGMP

Office stock sterile Illinois: not via ordinary 503A—needs 503B path ( 1330.640(c) ) Designed for non-patient-specific compounding under 503B conditions

Adverse events / reporting Standard pharmacy professional/state duties Explicit FDA adverse-event reporting expectations in the 503B model

Wholesale distribution Generally not a drug wholesaler by compounding alone Illinois sterile office-use path pairs 503B with wholesale distributor licensure

Exam sentence to memorize: 503A = patient-specific pharmacy compounding under USP/state rules; 503B = FDA-registered outsourcing facility under cGMP that may compound without patient-specific prescriptions.

Inspection Readiness for Compounding Areas

IDFPR investigators and annual self-inspection ( 1330.800 ) both expect compounding sites to prove control—not merely claim “we follow USP.”

Ready-to-produce packet

Pharmacy license reflecting current services; documentation of Department inspection/approval if sterile compounding was added after initial licensure ( 1330.640(i) )

Policies/procedures for nonsterile, sterile, and hazardous-drug workflows as applicable

Master formulation records and compounding records with component lots, expirations, BUDs, and identities of compounders/verifiers

Training/competency files for every pharmacist, student pharmacist, and technician who compounds ( 1330.640(h) )—current and specific to the dosage forms/risks

USP Compounding Compendium access and sterile compatibility/stability references

Equipment logs (balances, PECs certification concepts, temperature monitoring for refrigerators/freezers used for compounds)

  • Environmental control evidence for off-site deliveries (temperature-controlled containers, shipping SOPs)
  • Office-use logs if nonsterile office-use or veterinary office-use is performed
  • Hazardous-drug list, PPE inventory, spill kits, containment equipment, and waste procedures if HDs are handled
  • Patient profiles and 5-year readily retrievable audit trails ( 1330.640(e)(8)(D) )
  • Common inspection failures (and MPJE traps)

Finding Why it fails

Compounding on the counseling counter next to food/drinks No exclusive compounding area; sanitary/control failure

  • No BUD or wrong BUD for aqueous non-preserved liquid USP <795> framework ignored
  • Sterile prep without approved area / no PEC <797> + 1330.640(i) failure
  • Missing “specifically compounded for you” label statement 1330.640 labeling violation
  • Selling sterile non-patient-specific stock to clinics 1330.640(c) / 503A boundary violation
  • Training “done verbally years ago,” no documentation 1330.640(h) documentation failure
  • Cannot produce lot numbers of ingredients for last month’s batch Logbook/audit-trail failure
  • Worked Vignettes

Vignette 1 — BUD. Pharmacist compounds a non-preserved aqueous oral liquid without stability studies and assigns a 6-month room-temperature BUD. Problem: revised <795> default logic points to a short refrigerated BUD (commonly 14 days ), not months at room temperature.

Vignette 2 — Office-use label. Nonsterile office-use jar leaves the pharmacy labeled only with drug name and pharmacy phone, no “For Office Use Only – Not for Resale,” no BUD. Violation of 1330.640(d)(5) .

Vignette 3 — 503A vs 503B. Medical office wants weekly non-patient-specific sterile irrigation stock from a community pharmacy that is not a 503B facility. Refuse under 1330.640(c) ; discuss patient-specific prescriptions or a lawful outsourcing facility source.

Vignette 4 — Inspection. Investigator asks for sterile compounding training files; PIC says “everyone trained themselves on YouTube.” Failure of documented adequate training under 1330.640(h) .

Vignette 5 — Central fill anticipatory. Two commonly owned pharmacies under a Section 25.5 central-fill arrangement compound a modest anticipatory quantity of a nonsterile preparation based on routine demand. Potentially lawful under the anticipatory/central-fill pathway—contrast with open-market sales to unaffiliated clinics.

Study Checklist

BUD ≠ manufacturer expiration ; use <795>/<797> frameworks and stability data.

Memorize high-yield nonsterile default anchors (14-day refrigerated non-preserved aqueous; 35-day preserved aqueous; 90-day nonaqueous oral liquid) and Category 1 sterile short BUDs (12h RT / 24h fridge anchors).

Illinois default: patient-specific Rx ; know nonsterile office-use vs sterile office-use ban without 503B+wholesale path.

Labels: components, BUD , and “specifically compounded for you…” statement; office-use jars need “For Office Use Only – Not for Resale.”

Records: lots, expirations, BUDs, 5 years , MFR + CR.

503A patient-specific USP/state model vs 503B FDA/cGMP outsourcing model.

Inspection day: training files, approved sterile area, temperature-controlled shipping, exclusive compounding space.

Master BUDs and 1330.640 operations and you convert compounding from abstract USP chapter numbers into the decision rules Illinois MPJE items actually test—completing Area 4’s compounding strand before final test-day strategy in Chapter 14.